Olema Pharmaceuticals (NASDAQ:OLMA) and Otonomy (NASDAQ:OTIC) Critical Comparison
Olema Pharmaceuticals (NASDAQ:OLMA) and Otonomy (NASDAQ:OTIC) Critical Comparison
Olema Pharmaceuticals (NASDAQ:OLMA – Get Rating) and Otonomy (NASDAQ:OTIC – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk and earnings.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Olema Pharmaceuticals and Otonomy, as reported by MarketBeat.
Get Olema Pharmaceuticals alerts:Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Olema Pharmaceuticals | 0 | 0 | 3 | 0 | 3.00 |
Otonomy | 0 | 2 | 1 | 0 | 2.33 |
Olema Pharmaceuticals presently has a consensus target price of $14.33, suggesting a potential upside of 268.47%. Otonomy has a consensus target price of $3.25, suggesting a potential upside of 2,895.39%. Given Otonomy's higher probable upside, analysts clearly believe Otonomy is more favorable than Olema Pharmaceuticals.
Volatility and Risk
Olema Pharmaceuticals has a beta of 2.36, indicating that its share price is 136% more volatile than the S&P 500. Comparatively, Otonomy has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500.
Insider and Institutional Ownership
82.4% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 41.2% of Otonomy shares are held by institutional investors. 21.1% of Olema Pharmaceuticals shares are held by insiders. Comparatively, 1.1% of Otonomy shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Olema Pharmaceuticals and Otonomy's gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Olema Pharmaceuticals | N/A | N/A | -$71.10 million | ($2.62) | -1.48 |
Otonomy | $130,000.00 | 57.20 | -$51.18 million | ($0.77) | -0.14 |
Otonomy has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Otonomy, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Olema Pharmaceuticals and Otonomy's net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Olema Pharmaceuticals | N/A | -43.72% | -41.36% |
Otonomy | N/A | -137.86% | -68.50% |
Summary
Olema Pharmaceuticals beats Otonomy on 7 of the 12 factors compared between the two stocks.
About Olema Pharmaceuticals
(Get Rating)
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
About Otonomy
(Get Rating)
Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.
Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
奧萊馬製藥(納斯達克:OLMA-GET評級)和奧特梅尼(納斯達克:OICAL-GET評級)都是小盤醫療公司,但哪隻股票更優越?我們將根據這兩家公司的估值、機構所有權、分析師建議、盈利能力、股息、風險和收益的實力進行比較。
分析師建議
據MarketBeat報道,這是Olema製藥公司和Otmey公司目前的評級和目標價的細目。
到達奧萊馬製藥公司警報:銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
奧萊馬製藥公司 | 0 | 0 | 3 | 0 | 3.00 |
眼球運動 | 0 | 2 | 1 | 0 | 2.33 |
奧萊馬製藥公司目前的共識目標價為14.33美元,這意味著潛在的上漲268.47%。Otmey的共識目標價為3.25美元,暗示潛在上行空間為2895.39%。考慮到Otomy更有可能的上行空間,分析師顯然認為Otomy比Olema製藥公司更有利。
波動性和風險
Olema PharmPharmticals的貝塔係數為2.36,表明其股價的波動性比標準普爾500指數高136%。相比之下,Otmey的貝塔係數為1.58,這表明其股價的波動性比標準普爾500指數高58%。
內部人與機構持股
奧萊馬製藥82.4%的股份由機構投資者持有。相比之下,Otmey 41.2%的股份由機構投資者持有。奧萊馬製藥21.1%的股份由內部人士持有。相比之下,Otmey 1.1%的股份由內部人士持有。強大的機構持股表明,對沖基金、大型基金管理公司和捐贈基金相信,一隻股票的長期表現將好於大盤。
收益與估值
此表比較了Olema製藥公司和Otmey公司的總收入、每股收益和估值。
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 本益比 | |
奧萊馬製藥公司 | 不適用 | 不適用 | -7,110萬美元 | (2.62美元) | -1.48 |
眼球運動 | 130,000.00美元 | 57.20 | -5,118萬美元 | (0.77美元) | -0.14 |
Otomy的收入和收益比Olema製藥公司高。Olema PharmPharmticals的本益比低於Otmey,表明它目前是兩只股票中更負擔得起的一隻。
盈利能力
此表比較了Olema製藥公司和Otmey公司的淨利潤率、股本回報率和資產回報率。
淨利潤率 | 股本回報率 | 資產回報率 | |
奧萊馬製藥公司 | 不適用 | -43.72% | -41.36% |
眼球運動 | 不適用 | -137.86% | -68.50% |
摘要
Olema PharmPharmticals在兩只股票之間進行比較的12個因素中有7個超過了Otmey。
奧萊馬製藥公司簡介
(獲取評級)
奧萊瑪製藥公司是一家臨床階段的生物製藥公司,專注於女性癌症療法的發現、開發和商業化。它的主要候選產品是OP-1250,一種雌激素受體(ER)拮抗劑和選擇性ER降解劑,正處於1/2期臨床試驗,用於治療復發、局部晚期或轉移性雌激素受體陽性、人表皮生長因數受體2陰性的乳腺癌。該公司前身為CombiThera,Inc.,並於2009年3月更名為Olema製藥公司。奧萊馬製藥公司成立於2006年,總部設在加利福尼亞州舊金山。
關於Otomy
(獲取評級)
Otomy,Inc.是一家生物製藥公司。致力於神經病學治療學的發展。該公司的產品線包括OTIVIDEX(地塞米鬆)Meniere‘s病,Otiprio(環丙沙星耳用混懸液)急性中耳炎管狀(AOMT),OTO-313(加環利定)耳鳴,OTO-413(BDNF)隱性聽力損失,OTO-510(耳保護劑)防止CIHL,OTO-6XX(毛細胞再生)嚴重聽力損失。它以Otiprio品牌運營。該公司由Jay B.Lichter、Jeffrey Harris、Rick Friedman和Allen F.Ryan於2008年5月6日創立,總部設在加利福尼亞州聖地亞哥。
接受《奧萊馬藥業日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Olema製藥公司和相關公司的最新新聞和分析師評級的每日摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧